Drug Trial Radar · NCT07021976
A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
228
Actual
Start
Aug 11, 2025
Primary completion
Sep 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy.
Conditions
- Obstructive Hypertrophic Cardiomyopathy
Interventions
HRS-1893 TabletsDrug
HRS-1893 tablets.
HRS-1893 Placebo TabletsDrug
HRS-1893 placebo tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The clinical response rate of treatment with HRS-1893.Time frame: After 24 weeks of HRS-1893 treatment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.